Concepedia

Chanelle Wimbish

CW

Statistics

Publications

3

Citations

245

H-Index

3

Active since

2021

Affiliations

Johns Hopkins Medicine(Current)

Johns Hopkins University

Social and Scientific Systems (United States)

Stellenbosch University

University of California San Diego

Chanelle Wimbish is an author at Johns Hopkins Medicine specializing in pharmacotherapy, infectious diseases, and rifampicin therapy.

Publications per year

2021–2024

3

Publications

3

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie et al. · The Lancet Infectious Diseases · 2021 · 124 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Sunil S. Solomon, Sandra Wagner-Cardoso, Laura Smeaton et al. · The Lancet. Gastroenterology & hepatology · 2022 · 108 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy

Cynthia L. Gay, Ronald J. Bosch, Ashley McKhann et al. · Open Forum Infectious Diseases · 2024 · 13 citations · Full text

Life Sciences, Immunology, Infectious Diseases +13

1–3 of 3